John Parkinson

Emory’s Jill Morgan, RN, BSN, discusses what they do after removal of personal protective equipment (PPE) and if a provider has experienced a potential exposure to a high-consequence infectious disease.

Emory’s Jill Morgan, RN, BSN, provides an overview of putting on and taking off personal protective equipment (PPE) when caring for these patients.

Emory’s Katherine Normile, ASCP-MLS, discusses their protocols for safely donning and doffing their equipment when caring for patients with high-consequence infectious disease (HCID) as well as the process for receiving specimens in these care scenarios.

Infectious disease pediatrician Sharon Nachman, MD, offers insights on the incidence trends among teens, and what severe disease complications look like for young children.

Sharon Carrasco DNP, APRN, ACNS-BC, ANP-C, CEN, FAEN, FAAN, FNAP, discusses her approach to training for these care scenarios.

Former FDA Chief Scientist Jesse L. Goodman, MD, MPH, provides insights on the potential consequences of these new recommendations.

Sharon Carrasco DNP, APRN, ACNS-BC, ANP-C, CEN, FAEN, FAAN, FNAP, talks about safely responding to deadly pathogens such as Ebola and Lassa fever, and where the US is in terms of thinking about preparedness on a national level.

Jill Morgan, RN, BSN, talks about steps being taken to ensure everyone’s safety is front of mind.

The recent CDC ACIP meetings and subsequent actions show a path for which the current Health and Human Services department wants to roll back access to vaccines for this virus and other vaccines.

Jill Morgan, RN, BSN, reviews this significant part of clinical care and how personal protective equipment (PPE) is essential to protecting healthcare workers.

Emory's Gavin Harris, MD, discusses these elements, and how despite the fact they rarely occur, the need to do continuous training is essential for readiness.

Gavin Harris, MD, discusses his experience working in outbreak environments where there is high-consequence infectious disease (HCID) and how it is important to establish buy-in from the local populations and some of the important elements of what you need to leave behind when an outbreak is declared over.

Emory's Gavin Harris, MD, talks about taking care of patients with high-consequence infectious diseases, and considerations for not only their care, but their families. He also discusses working with other healthcare facilities around COVID-19 care and educating them through Emory's ECHO program on new and existing threats.

Jonathan Parr, MD, MPH, discusses his work in locating potential targets to develop a syphilis vaccine and the challenges associated with genomic diversity of subpopulations of the main pathogen, Treponema pallidum.

This new recommendation relates to infants born to women who test negative for hepatitis B. This is a departure from the federal agency’s previous recommendation and comes on the heels of the ACIP’s recent meeting.

Andrew Handel, MD, talks about transmission, differential diagnosis, treatment, and protection against it.

Margaret Aldrich, MD, provides insight around this concept, addressing stewardship within this patient population, and how their institution’s collaborative work environment helps all of the department’s clinicians.

The antibiotic's approval was based from phase 3 results demonstrating noninferiority to a combination therapy.

Infectious disease pediatrician Sharon Nachman, MD, talks about how the new recommendations will defer immunization, leading to a whole host of issues and negative impacts on long-term public health.

GSK’s David Payne, PhD, provides more information are the data from the EAGLE-1 trial.

The federal nod was given based from the phase 3 data of the EAGLE-1 trial, which showed noninferiority to combination therapy. This approval provides a new oral option.

NYU Langone’s Angelica Cifuentes Kottkamp, MD, continues our Media Day discussion around these illnesses and how in New York City, clinicians need to be prepared to decipher in differential diagnosis for these potential diseases.

In episode 2 of our Media Day series with NYU Langone, Angelica Cifuentes Kottkamp, MD, discusses its vaccine center and their work around COVID-19 vaccines, as well as the importance of achieving diversity in clinical trials.

Robert Hopkins Jr, MD, medical director of the National Foundation for Infectious Diseases, discusses the changes in the new vaccine recommendations and what potential serious consequences may be seen as a result.

Angelica Cifuentes Kottkamp, MD, discusses how its location, breadth of experience, and opportunities afford clinicians the ability to see and treat a wide berth of diseases and infections.

Lacking any safety data showing potential serious adverse effects, the committee decided to move forward with the recommendation “that the initial dose is administered no earlier than 2 months of age.”

Due to repetitive and confusing language, the committee decided to amend the votes for clarity and will vote on 3 new recommendations on Friday.

A new analysis shows thousands of children could contract hepatitis B, leading to further complications and deaths, if the vaccine schedule recommendations are changed to later in a child's life.

The New Jersey company recently announced the partnership that includes federal funding to create new treatments from a novel class of fungerps.

Shionogi has been identifying in vitro activity using its antibiotic, cefiderocol, against Gram-negative clinical isolates such as carbapenem-resistant Enterobacterales (CRE). Christine Slover, PharmD, offers some insights on the company’s analysis.